Full-Time

Senior Validation Engineer

Posted on 9/23/2025

Forge Biologics

Forge Biologics

201-500 employees

End-to-end manufacturing of AAV gene therapies

No salary listed

Columbus, OH, USA

In Person

Onsite in Columbus, Ohio; 4-5 days/week.

Category
QA & Testing (1)
Required Skills
Minitab
Data Analysis
Requirements
  • Bachelor's or degree in Engineering, Biotechnology, Pharmaceutical Sciences, or a related field (or equivalent experience)
  • Knowledge of validation principles across multiple disciplines, which may include process validation, aseptic process simulation, equipment qualification, and/or computer systems
  • Significant experience in process validation within the pharmaceutical or biotechnology industry
  • Strong understanding of Quality by Design (QbD) principles with proficiency in risk assessment methodologies (e.g., PFMEA) and statistical analysis tools for validation data (e.g., Minitab, JMP)
  • Strong understanding of cGMPs (current Good Manufacturing Practices)
  • Excellent analytical, problem-solving, and decision-making skills, with meticulous attention to detail
  • Effective communication and collaboration abilities, with the capacity to work cross-functionally and influence stakeholders at various levels of the organization
  • Strong project management skills, with the ability to prioritize and manage multiple validation projects concurrently
  • Experience in the application of commercial cGMPs
  • Experience with aseptic processing and clean room standards
  • Ability to work onsite (Columbus, Ohio) 4-5 days/week on average
Responsibilities
  • Develop, Implement, and Maintain the Process Performance Qualification (PPQ) and Continued Process Validation (CPV) programs, including development of related procedures, templates, work instructions, and associated documentation
  • Develop and lead execution of Process Performance Qualification (PPQ) protocols, for GMP manufacturing processes
  • Maintain and provide continuous improvement of the Aseptic Process Simulation (APS) (Media Fill) program
  • Develop and lead execution of new aseptic (APS) protocols, for aseptic manufacturing processes
  • Collaborate with cross-functional teams, including Process & Analytical Development, GMP Manufacturing, Operations , Manufacturing Science and Technology (MSAT), Quality Management, Quality Control, and Regulatory Affairs to ensure effective planning, execution, and completion of validation activities
  • Define sampling plans and, test methods, and acceptance criteria for validation deliverables, ensuring alignment with regulatory guidelines (FDA, EMA, etc.), industry best practices, and internal procedures
  • Lead and participate in investigations related to validation deviations, implementing appropriate corrective and preventive actions (CAPAs) as needed
  • Assess changes to proposed process changes and develop validation plans, as necessary
  • Conduct hands-on validation activities, such as protocol generation, execution, data analysis, and report writing
  • Collaborate on risk management, process development studies, technology transfer, and other process validation related activities
  • Stay abreast of industry trends, regulatory updates, and technological advancements related to process validation in the cell and gene therapy field and propose continuous improvement initiatives to enhance validation processes and practices
  • Provide technical guidance and mentorship to junior team members, fostering a culture of knowledge sharing and professional development
  • Support Equipment, Facility, and Utility Commissioning and Qualification efforts, as necessary
Desired Qualifications
  • Process Validation experience in the Cell & Gene Therapy Industry
  • Experience in qualifying a wide range of equipment, including Biological Safety Cabinets (BSCs), Controlled Temperature Units (CTUs), bioreactors, incubators, chromatography systems, centrifuges, and analytical instruments
  • Experience in the application of pre-clinical and clinical cGMPs
  • Experience with Cleaning Validation

Forge Biologics provides end-to-end development and manufacturing for gene therapies, using its gene therapy development engine to move ideas from the lab into scalable production. It focuses on AAV-based therapies and operates from Hearth, a large cGMP facility designed for manufacturing at scale. Revenue comes from offering manufacturing services to other companies and researchers, while also developing its own therapies for potential future products. Its goal is to become a leading, integrated manufacturing partner for gene therapies, helping rare genetic-disease programs reach the clinic and market.

Company Size

201-500

Company Stage

Acquired

Total Funding

$870M

Headquarters

Columbus, Ohio

Founded

2020

Simplify Jobs

Simplify's Take

What believers are saying

  • Eight ASGCT presentations in May 2025 highlight FUEL™ manufacturing innovations.
  • John Maslowski became CEO on October 1, 2024, driving commercial growth.
  • Partnerships with Affinia, Progeria Foundation, and Fractyl expand revenue pipelines.

What critics are saying

  • Ajinomoto diverts resources to larger CDMOs, diluting Forge's AAV focus within 12-24 months.
  • Hearth facility saturates from Progeria, Affinia, Fractyl partnerships, delaying production in 12-18 months.
  • Catalent's $16.5B acquisition floods AAV capacity, undercutting Forge pricing in 6-12 months.

What makes Forge Biologics unique

  • FUEL™ platform boosts AAV productivity, recovery, and quality using Ignition Cells™ and pEMBR™ 2.0.
  • 200,000 sq ft Hearth facility houses 20 cGMP suites with 20,000L bioreactor capacity.
  • End-to-end services span plasmid DNA, AAV manufacturing, and regulatory support.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Unlimited Paid Time Off

401(k) Company Match

Annual Bonus

Paid Parental Leave

Employee Assistance Program

Wellness Program

Onsite Fitness Facility

Company News

University of Pittsburgh
Apr 22nd, 2026
Innovation Institute Reports Record Number of Invention Disclosures, Despite Pandemic

From swimming devices to rare disease gene therapies, Pitt inventors never stop: The Innovation Institute reported a record 394 invention disclosures for last fiscal year, and Director Evan Facher says another robust year is ahead.

Contract Pharma
Mar 3rd, 2026
Progeria Research Foundation, Forge Biologics Enter Gene Therapy Mfg. Pact

Progeria Research Foundation, Forge Biologics enter gene therapy mfg. Pact. Forge Biologics will provide process development and manufacturing services to support gene therapy for ultrarare disease. March 3, 2026 Managing Editor, Contract Pharma The Progeria Research Foundation (PRF), a research organization developing treatments for Hutchinson-Gilford Progeria Syndrome, and Forge Biologics, a manufacturer of gene therapies, entered a manufacturing agreement to support the development and manufacture of SamPro-2, PRF's investigational gene therapy for adolescence with Progeria, an ultrarare and fatal genetic disease characterized by rapid aging. The manufacturing agreement leverages PRF's research-driven Progeria program with Forge's integrated gene therapy capabilities including process development, cGMP manufacturing, FUEL platform technologies, and regulatory consultation. Forge will provide manufacturing services for Investigative New Drug (IND)-enabling studies with SamPro-2, a gene therapy that uses adeno-associated virus (AAV), a commonly utilized delivery vehicle in gene therapy, to deliver a base editing approach designed to correct the single DNA base mutation in the lamin A gene that causes Progeria. "Behind every program like this are patients and families who have waited a long time for progress," said John Maslowski, president and chief executive officer of Forge Biologics. "The Progeria Research Foundation and its Gene Team have shown extraordinary dedication to advancing this science, and we are honored to partner with them. At Forge, we bring that same level of care, expertise, and technical rigor to our manufacturing work as we help advance this program for patients."

PharmaSource
May 15th, 2025
Forge Biologics Partners with Fractyl Health on AAV Manufacturing for Metabolic Gene Therapy

Forge Biologics partners with Fractyl Health on AAV manufacturing for metabolic gene therapy.

BioSpace
May 14th, 2025
Forge Biologics Announces Eight Presentations At The American Society Of Gene And Cell Therapy (Asgct) 28Th Annual Meeting

Oral and poster presentations will highlight data demonstrating the enhanced productivity, recovery, and consistent quality of Forge’s FUEL™ AAV manufacturing platform, addressing the industry's need for more efficient manufacturingCOLUMBUS, Ohio--(BUSINESS WIRE)--Forge Biologics (“Forge”), a leading manufacturer of genetic medicines and member of the Ajinomoto Bio-Pharma Services group, today announced that it will deliver eight presentations at the upcoming American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting, taking place May 13-17, 2025 in New Orleans, Louisiana. The presentations include two technical session presentations, an oral presentation, and five scientific posters focused on Forge’s FUEL™ platform and manufacturing innovations for gene therapies.“We’re proud to share Forge’s latest manufacturing advancements, underscoring our commitment to innovation as we help clients deliver transformative gene therapies to patients,” said John Maslowski, CEO and President of Forge. “Our experts will highlight how the FUEL™ AAV manufacturing platform, with its advanced technologies and product-specific optimizations, drives significant productivity gains. We’re also excited to present additional talks and posters on key analytical advances as we look toward a future of faster and more comprehensive analytics for product release.”SESSION PRESENTATIONSSponsored Symposium. Title: “Great Science Needs Innovative Manufacturing Technology”. Presenters:David Dismuke, Ph.D., Chief Technology Officer

BioProcess International
Nov 15th, 2024
Affinia and Forge team up to tackle cardiovascular diseases

Affinia Therapeutics announced that it is partnering with Forge Biologics to manufacture clinical trial material under GMP standards.

INACTIVE